Adlai Nortye Ltd. and Nucleai, two prominent biotechnology companies, have been awarded the ESMO 2023 Best Poster Award for their innovative study on Buparlisib in head and neck cancer. The study, titled Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN, showcased a novel methodology for identifying patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who are likely to benefit from combination Buparlisib + paclitaxel treatment.
The study focused on utilizing artificial intelligence (AI) technology to analyze H&E images and identify spatial features associated with clinical outcomes. By analyzing these images, the researchers aimed to predict which patients would respond positively to the combination treatment, ultimately providing safer and more effective therapies.
We are extremely pleased that the study received recognition for its quality and success, said Dr. Lars Birgerson, President & CMO of Adlai Nortye. Identifying suitable candidates for Buparlisib + paclitaxel therapy in metastatic SCCHN patients is a crucial step in delivering timely and life-saving treatments.
Oscar Puig, VP of Translational Medicine and Diagnostics at Nucleai, expressed excitement about bringing novel spatial biomarkers to the forefront of drug research and development. The companies plan to further validate these findings through their partnership.
The award-winning poster, presented at the Head and Neck Cancers poster session on October 22, 2023, showcased the potential of Buparlisib (AN2025). Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and has demonstrated activity in hematologic malignancies and solid tumors. It is currently being studied in the global Phase III BURAN study (NCT04338399) for metastatic SCCHN.
The BURAN study is a randomized, open-label, multicenter phase III study that aims to assess the treatment effect of once-daily Buparlisib in combination with weekly paclitaxel compared to paclitaxel alone. The study focuses on patients with recurrent or static head and neck squamous cell carcinoma (HNSCC) that has progressed after prior anti-PD-1/anti-PD-L1 monotherapy or other treatment combinations.
Adlai Nortye is a global clinical-stage biotechnology company that prioritizes innovative oncology drugs. With R&D and global clinical operation centers in China and the U.S., the company has built a robust pipeline with six drug candidates in development. Three of these candidates, including Buparlisib, are currently being investigated in multiple clinical trials.
Nucleai, on the other hand, is an AI-driven biomarker and diagnostics company that focuses on digital pathology and spatial biology. Leveraging cutting-edge AI platforms, Nucleai supports pharmaceutical companies, contract research organizations, and diagnostics laboratories in improving clinical trials and developing AI-powered diagnostics.
Adlai Nortye and Nucleai’s collaboration in this study exemplifies the importance of merging advanced technologies and scientific expertise to foster groundbreaking advancements in cancer diagnosis and treatment. By analyzing H&E images with AI-based structuring, the researchers have taken a significant step towards personalized medicine and optimized treatment strategies.
Both companies remain committed to their mission of benefiting patients worldwide and transforming life-threatening cancer into a chronic and ultimately curable disease. Through groundbreaking research and strategic collaborations, Adlai Nortye and Nucleai continue to drive innovation in the field of oncology.
For more information about Adlai Nortye and their pipeline, please visit www.adlainortye.com. To learn more about Nucleai and their AI-driven biomarker discoveries, visit www.nucleai.ai.
